Kymera Therapeutics, Inc. (KYMR)

Market Cap	3.49B
Revenue (ttm)	44.71M
Net Income (ttm)	-275.43M
Shares Out	71.50M
EPS (ttm)	-3.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	894,833
Open	48.00
Previous Close	47.28
Day's Range	47.87 - 49.72
52-Week Range	19.45 - 53.27
Beta	2.18
Analysts	Strong Buy
Price Target	59.25 (+21.46%)
Earnings Date	Oct 30, 2025

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat aut...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 21, 2020
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: KYMR
• Website: https://www.kymeratx.com

Financial Performance

In 2024, Kymera Therapeutics's revenue was $47.07 million, a decrease of -40.11% compared to the previous year's $78.59 million. Losses were -$223.86 million, 52.3% more than in 2023.

Analyst Summary

According to 16 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $59.25, which is an increase of 21.46% from the latest price.

Price Target

$59.25

(21.46% upside)

Analyst Consensus: Strong Buy